Michael Cruse - 29 Aug 2022 Form 4 Insider Report for Reneo Pharmaceuticals, Inc. (OKUR)

Signature
/s/ Michael Cruse
Issuer symbol
OKUR
Transactions as of
29 Aug 2022
Net transactions value
+$23,243
Form type
4
Filing time
31 Aug 2022, 17:47:43 UTC
Previous filing
04 Mar 2022
Next filing
02 Sep 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RPHM Common Stock Purchase $269 +83 +0.27% $3.24 30,783 29 Aug 2022 Direct F1
transaction RPHM Common Stock Purchase $3,694 +1,140 $3.24 1,140 29 Aug 2022 by Trust F2
transaction RPHM Common Stock Purchase $3,081 +975 +3.2% $3.16 31,758 30 Aug 2022 Direct F3
transaction RPHM Common Stock Purchase $5,893 +1,845 +162% $3.19 2,985 30 Aug 2022 by Trust F2, F4
transaction RPHM Common Stock Purchase $10,307 +3,212 +108% $3.21 6,197 31 Aug 2022 by Trust F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 1,600 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan on June 8, 2022.
F2 By Michael P. Cruse and Thu Anh Thuy Cruse, Trustees of The Cruse Family Revocable Living Trust.
F3 The weighted average purchase price for the transaction was $3.16. The shares were purchased at a range of prices between $3.11 and $3.19. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
F4 The weighted average purchase price for the transaction was $3.1938. The shares were purchased at a range of prices between $3.16 and $3.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
F5 The weighted average purchase price for the transaction was $3.209. The shares were purchased at a range of prices between $3.19 and $3.29. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.